Latest filings (excl ownership)
ARS
2014 FY
Annual report to shareholders
28 Apr 15
15-12B
Securities registration termination
15 Jan 15
EFFECT
Notice of effectiveness
14 Jan 15
EFFECT
Notice of effectiveness
14 Jan 15
25-NSE
Exchange delisting
13 Jan 15
8-K
Completion of Acquisition or Disposition of Assets
13 Jan 15
POS AM
Prospectus update (post-effective amendment)
13 Jan 15
POS AM
Prospectus update (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
SC 14D9/A
Tender offer solicitation (amended)
13 Jan 15
SC TO-T/A
Third party tender offer statement (amended)
13 Jan 15
SC TO-T/A
Third party tender offer statement (amended)
6 Jan 15
SC 14D9/A
Tender offer solicitation (amended)
5 Jan 15
SC TO-T/A
Third party tender offer statement (amended)
5 Jan 15
SC 14D9/A
Tender offer solicitation (amended)
2 Jan 15
SC TO-T/A
Third party tender offer statement (amended)
31 Dec 14
SC 14D9
Tender offer solicitation
12 Dec 14
SC TO-T
Third party tender offer statement
12 Dec 14
SC14D9C
Written communication relating to third party tender offer
11 Dec 14
10-K
2014 FY
Annual report
10 Dec 14
SC TO-C
Information about tender offer
10 Dec 14
8-K
Avanir Pharmaceuticals to Be Acquired by Otsuka
2 Dec 14
SC TO-C
Information about tender offer
2 Dec 14
SC14D9C
Written communication relating to third party tender offer
2 Dec 14
SC14D9C
Written communication relating to third party tender offer
2 Dec 14
8-K
Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA
28 Nov 14
8-K
Departure of Directors or Certain Officers
12 Nov 14
8-K
Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine
7 Nov 14
Latest ownership filings
SC 13G/A
Avanir Pharmaceuticals, Inc.
11 Feb 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
10 Feb 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
9 Feb 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
26 Jan 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
12 Jan 15
SC 13G/A
Beneficial ownership report (amended)
10 Nov 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
10 Nov 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
12 Sep 14
SC 13G
Avanir Pharmaceuticals, Inc.
10 Jun 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
14 Feb 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
14 Feb 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
11 Feb 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
10 Feb 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
7 Feb 14
SC 13G
Avanir Pharmaceuticals, Inc.
3 Feb 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
28 Jan 14
SC 13D/A
Clarus Lifesciences I, L.P.
9 Dec 10
SC 13D/A
Clarus Lifesciences I, L.P.
9 Nov 10